<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Ritonavir: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i400.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i400.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i400.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i391.htm">Antivirals</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i843.htm" title="Previous: Nevirapine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i791.htm" title="Next: Saquinavir">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i400">Ritonavir</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Ritonavir</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i86.htm" name="_86">Alfentanil</a></td><td class="cBV"><b> ritonavir increases plasma concentration of alfentanil </b></td><td></td></tr><tr><td><a href="41001i30.htm" name="_30">Alfuzosin</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of alfuzosin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i406.htm" name="_406">Alprazolam</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of alprazolam (risk of extreme sedation and respiratory depression—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i118.htm" name="_118">Amiodarone</a></td><td class="cBV"><b> ritonavir increases plasma concentration of amiodarone (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i232.htm" name="_232">Antidepressants, SSRI</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of SSRIs </b></td><td></td></tr><tr><td><a href="41001i241.htm" name="_241">Antidepressants, Tricyclic</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of tricyclics </b></td><td></td></tr><tr><td><a href="41001i304.htm" name="_304">Antihistamines, Non-sedating</a></td><td> ritonavir possibly increases plasma concentration of non-sedating antihistamines </td><td></td></tr><tr><td><a href="41001i363.htm" name="_363">Antipsychotics</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of antipsychotics </b></td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i404.htm" name="_404">Anxiolytics and Hypnotics</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of anxiolytics and hypnotics </b></td><td></td></tr><tr><td><a href="41001i1217.htm" name="_1217">Apixaban</a></td><td>avoidance of  ritonavir advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1010.htm" name="_1010">Aprepitant</a></td><td> ritonavir possibly increases plasma concentration of aprepitant </td><td></td></tr><tr><td><a href="41001i1011.htm" name="_1011">Aripiprazole</a></td><td class="cBV"><b> ritonavir possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i937.htm" name="_937">Artemether with Lumefantrine</a></td><td>caution with  ritonavir advised by manufacturer of artemether/lumefantrine </td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  ritonavir given with atorvastatin </td><td></td></tr><tr><td><a href="41001i167.htm" name="_167">Azithromycin</a></td><td> ritonavir possibly increases plasma concentration of azithromycin </td><td></td></tr><tr><td><a href="41001i943.htm" name="_943">Bosentan</a></td><td class="cBV"><b> ritonavir increases plasma concentration of bosentan </b></td><td></td></tr><tr><td><a href="41001i496.htm">Budesonide</a></td><td> ritonavir increases plasma concentration of <i>inhaled</i> and <i>intranasal</i> budesonide </td><td></td></tr><tr><td><a href="41001i87.htm" name="_87">Buprenorphine</a></td><td> ritonavir possibly increases plasma concentration of buprenorphine </td><td></td></tr><tr><td><a href="41001i896.htm" name="_896">Bupropion</a></td><td> ritonavir reduces plasma concentration of bupropion </td><td></td></tr><tr><td><a href="41001i427.htm" name="_427">Buspirone</a></td><td> ritonavir increases plasma concentration of buspirone (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i1204.htm" name="_1204">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  ritonavir advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i466.htm" name="_466">Calcium-channel Blockers</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of calcium-channel blockers </b></td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i277.htm" name="_277">Carbamazepine</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i499.htm" name="_499">Ciclosporin</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of ciclosporin </b></td><td></td></tr><tr><td><a href="41001i168.htm" name="_168">Clarithromycin</a></td><td class="cBV"><b> ritonavir increases plasma concentration of clarithromycin (reduce dose of clarithromycin in renal impairment)</b></td><td></td></tr><tr><td><a href="41001i364.htm" name="_364">Clozapine</a></td><td class="cBV"><b> ritonavir increases plasma concentration of clozapine (increased risk of toxicity)—avoid concomitant use</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i483.htm" name="_483">Colchicine</a></td><td class="cBV"><b> ritonavir possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i484.htm" name="_484">Corticosteroids</a></td><td> ritonavir possibly increases plasma concentration of corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm" name="_220">Coumarins</a></td><td class="cBV"><b> ritonavir possibly enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1076.htm" name="_1076">Darifenacin</a></td><td>avoidance of  ritonavir advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i490.htm" name="_490">Dexamethasone</a></td><td> ritonavir possibly increases plasma concentration of dexamethasone </td><td></td></tr><tr><td><a href="41001i714.htm" name="_714">Dexamfetamine</a></td><td> ritonavir possibly increases plasma concentration of dexamfetamine </td><td></td></tr><tr><td><a href="41001i90.htm" name="_90">Dextropropoxyphene</a></td><td class="cBV"><b> ritonavir increases plasma concentration of dextropropoxyphene (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i412.htm" name="_412">Diazepam</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of diazepam (risk of extreme sedation and respiratory depression—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i480.htm" name="_480">Digoxin</a></td><td> ritonavir possibly increases plasma concentration of digoxin </td><td></td></tr><tr><td><a href="41001i119.htm" name="_119">Disopyramide</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of disopyramide (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i516.htm" name="_516">Docetaxel</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of docetaxel (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1176.htm" name="_1176">Dronedarone</a></td><td class="cBV"><b>avoidance of  ritonavir advised by manufacturer of dronedarone </b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td> ritonavir increases toxicity of efavirenz , monitor liver function tests</td><td></td></tr><tr><td><a href="41001i963.htm" name="_963">Eletriptan</a></td><td class="cBV"><b> ritonavir increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm" name="_1025">Eplerenone</a></td><td class="cBV"><b> ritonavir increases plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i563.htm" name="_563">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  ritonavir given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm" name="_169">Erythromycin</a></td><td> ritonavir possibly increases plasma concentration of erythromycin </td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1169.htm" name="_1169">Everolimus</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i95.htm" name="_95">Fentanyl</a></td><td class="cBV"><b> ritonavir increases plasma concentration of fentanyl </b></td><td></td></tr><tr><td><a href="41001i1119.htm" name="_1119">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  ritonavir given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i120.htm" name="_120">Flecainide</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of flecainide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  ritonavir increased by fluconazole </td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i416.htm" name="_416">Flurazepam</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of flurazepam (risk of extreme sedation and respiratory depression—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i497.htm">Fluticasone</a></td><td class="cBV"><b> ritonavir increases plasma concentration of <i>inhaled</i> and <i>intranasal</i> fluticasone </b></td><td></td></tr><tr><td><a href="41001i163.htm">Fusidic Acid</a></td><td class="cBV"><b>plasma concentration of both drugs increased when  ritonavir given with fusidic acid—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i398.htm" name="_398">Indinavir</a></td><td> ritonavir increases plasma concentration of indinavir </td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>combination of  ritonavir with itraconazole may increase plasma concentration of either drug (or both)</b></td><td></td></tr><tr><td><a href="41001i1050.htm" name="_1050">Ivabradine</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of ivabradine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>combination of  ritonavir with ketoconazole may increase plasma concentration of either drug (or both)</b></td><td></td></tr><tr><td><a href="41001i283.htm" name="_283">Lamotrigine</a></td><td> ritonavir possibly reduces plasma concentration of lamotrigine </td><td></td></tr><tr><td><a href="41001i1128.htm" name="_1128">Lapatinib</a></td><td class="cBV"><b>avoidance of  ritonavir advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i846.htm" name="_846">Lercanidipine</a></td><td>avoidance of  ritonavir advised by manufacturer of lercanidipine </td><td></td></tr><tr><td><a href="41001i1107.htm" name="_1107">Maraviroc</a></td><td> ritonavir increases plasma concentration of maraviroc </td><td></td></tr><tr><td><a href="41001i97.htm" name="_97">Methadone</a></td><td> ritonavir reduces plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i98.htm" name="_98">Morphine</a></td><td> ritonavir possibly reduces plasma concentration of morphine </td><td></td></tr><tr><td><a href="41001i842.htm" name="_842">Nelfinavir</a></td><td>combination of  ritonavir with nelfinavir may increase plasma concentration of either drug (or both)</td><td></td></tr><tr><td><a href="41001i1118.htm" name="_1118">Nilotinib</a></td><td class="cBV"><b>avoidance of  ritonavir advised by manufacturer of nilotinib </b></td><td></td></tr><tr><td><a href="41001i60.htm" name="_60">NSAIDs</a></td><td> ritonavir possibly increases plasma concentration of NSAIDs </td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i636.htm" name="_636">Oestrogens</a></td><td class="cBV"><b> ritonavir accelerates metabolism of oestrogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i366.htm" name="_366">Olanzapine</a></td><td> ritonavir reduces plasma concentration of olanzapine—consider increasing dose of olanzapine</td><td></td></tr><tr><td><a href="41001i517.htm" name="_517">Paclitaxel</a></td><td> ritonavir increases plasma concentration of paclitaxel </td><td></td></tr><tr><td><a href="41001i236.htm" name="_236">Paroxetine</a></td><td> ritonavir possibly reduces plasma concentration of paroxetine </td><td></td></tr><tr><td><a href="41001i1186.htm" name="_1186">Pazopanib</a></td><td class="cBV"><b>avoidance of  ritonavir advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i102.htm">Pethidine</a></td><td class="cBV"><b> ritonavir reduces plasma concentration of pethidine , but increases plasma concentration of toxic metabolite of pethidine (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i223.htm" name="_223">Phenindione</a></td><td class="cBV"><b> ritonavir possibly enhances anticoagulant effect of phenindione </b></td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  ritonavir possibly reduced by phenytoin , also plasma concentration of phenytoin possibly affected</td><td></td></tr><tr><td><a href="41001i369.htm" name="_369">Pimozide</a></td><td class="cBV"><b> ritonavir increases plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i78.htm" name="_78">Piroxicam</a></td><td class="cBV"><b> ritonavir increases plasma concentration of piroxicam (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i486.htm" name="_486">Prednisolone</a></td><td> ritonavir possibly increases plasma concentration of prednisolone </td><td></td></tr><tr><td><a href="41001i125.htm" name="_125">Propafenone</a></td><td class="cBV"><b> ritonavir increases plasma concentration of propafenone (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i824.htm" name="_824">Quetiapine</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm" name="_341">Quinine</a></td><td class="cBV"><b> ritonavir increases plasma concentration of quinine (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1147.htm" name="_1147">Ranolazine</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> ritonavir increases plasma concentration of rifabutin (increased risk of toxicity—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  ritonavir possibly reduced by rifampicin </td><td></td></tr><tr><td><a href="41001i1136.htm" name="_1136">Rivaroxaban</a></td><td class="cBV"><b> ritonavir increases plasma concentration of rivaroxaban—manufacturer of rivaroxaban advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i974.htm" name="_974">Rosuvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  ritonavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i791.htm" name="_791">Saquinavir</a></td><td class="cBV"><b> ritonavir increases plasma concentration of saquinavir </b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td class="cBV"><b> ritonavir significantly increases plasma concentration of sildenafil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  ritonavir given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1020.htm" name="_1020">Solifenacin</a></td><td> ritonavir increases plasma concentration of solifenacin </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  ritonavir reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm" name="_730">Tacrolimus</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm" name="_945">Tadalafil</a></td><td class="cBV"><b> ritonavir increases plasma concentration of tadalafil—manufacturer of tadalafil advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1216.htm" name="_1216">Telaprevir</a></td><td> ritonavir possibly reduces plasma concentration of telaprevir </td><td></td></tr><tr><td><a href="41001i946.htm" name="_946">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  ritonavir in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> ritonavir accelerates metabolism of theophylline (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i1203.htm" name="_1203">Ticagrelor</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of ticagrelor—manufacturer of ticagrelor advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i275.htm" name="_275">Tolbutamide</a></td><td> ritonavir possibly increases plasma concentration of tolbutamide </td><td></td></tr><tr><td><a href="41001i850.htm" name="_850">Tolterodine</a></td><td>avoidance of  ritonavir advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i255.htm" name="_255">Trazodone</a></td><td class="cBV"><b> ritonavir increases plasma concentration of trazodone (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1163.htm" name="_1163">Ulipristal</a></td><td class="cBV"><b>avoidance of  ritonavir advised by manufacturer of ulipristal (contraceptive effect of ulipristal possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i967.htm" name="_967">Vardenafil</a></td><td class="cBV"><b> ritonavir increases plasma concentration of vardenafil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1002.htm" name="_1002">Vinblastine</a></td><td> ritonavir possibly increases plasma concentration of vinblastine </td><td></td></tr><tr><td><a href="41001i1181.htm" name="_1181">Vinflunine</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of vinflunine—manufacturer of vinflunine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i948.htm" name="_948">Voriconazole</a></td><td class="cBV"><b> ritonavir reduces plasma concentration of voriconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i222.htm" name="_222">Warfarin</a></td><td class="cBV"><b> ritonavir may enhance or reduce anticoagulant effect of warfarin </b></td><td></td></tr><tr><td><a href="41001i425.htm" name="_425">Zolpidem</a></td><td class="cBV"><b> ritonavir possibly increases plasma concentration of zolpidem (risk of extreme sedation and respiratory depression—avoid concomitant use)</b></td><td></td></tr></tbody></table><p>Ritonavir belongs to <b>Antivirals</b>
          but <b>Antivirals</b>
          has no interactions information.
        </p></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i843.htm">Previous: Nevirapine</a> | <a class="top" href="41001i400.htm#">Top</a> | <a accesskey="]" href="41001i791.htm">Next: Saquinavir</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>